secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001493152-22-031516
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix reports Q3 2022 revenue $1.9M, net loss $5.05M; PUR1900 Phase 2 on track for Q1 2023
--------------------------------------------------------------------------------

- Revenues $1.9M, up from $1.1M YoY; net loss $5.05M ($1.45 per share) vs $8.18M loss in prior year.
- Cash and equivalents $40.7M; expects to fund ops into Q2 2024; raised $1.4M via ATM at ~$5.70/share.
- PUR1900 Phase 2 study for ABPA to start dosing in Q1 2023; 16-week regimen.
- PUR3100 Phase 1 data for acute migraine anticipated early Q1 2023; database lock in November.
- PUR1800 Phase 1b data analysis ongoing for presentation at 2023 medical conference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315222031516/0001493152-22-031516-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315222031516/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-031516

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer